Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma

This is a Phase I/II clinical study conducted in participants with relapsed/refractory aggressive B-cell lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6055 Injection in participants with relapsed/refractory aggressive B-cell lymphoma, and to provide a basis for the recommended dosing regimen in subsequent studies.

NCT Number	NCT07476066
Lead Sponsor	Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
Conditions	Relapsed/Refractory Aggressive B-Cell Lymphoma
Enrollment	374 participants
Start Date	2026-03-15
Primary Completion	2029-03-15 (estimated)
Study Completion	2031-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-17